RAD51 and breast cancer: Our data further suggests that IGF-1R inhibition suppresses HR by downregulation of RAD51, and that this allows a strong antitumor activity in combination with PARP inhibitors in BRCA1 wild-type (HR proficient) ovarian and breast cancer cells.